$CORT
Corcept Therapeutics Inc

2020 Q1 Form 10-Q Financial Statement

#000162828020006270 Filed on May 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $93.25M $64.83M
YoY Change 43.84% 12.44%
Cost Of Revenue $1.878M $1.240M
YoY Change 51.45% 5.62%
Gross Profit $91.37M $63.59M
YoY Change 43.69% 12.58%
Gross Profit Margin 97.99% 98.09%
Selling, General & Admin $27.54M $24.39M
YoY Change 12.9% 32.26%
% of Gross Profit 30.14% 38.35%
Research & Development $26.12M $20.24M
YoY Change 29.04% 18.73%
% of Gross Profit 28.59% 31.84%
Depreciation & Amortization $238.0K $96.00K
YoY Change 147.92% 100.0%
% of Gross Profit 0.26% 0.15%
Operating Expenses $53.66M $44.63M
YoY Change 20.22% 25.76%
Operating Profit $37.71M $18.96M
YoY Change 98.94% -9.71%
Interest Expense $1.470M $1.100M
YoY Change 33.64% 279.31%
% of Operating Profit 3.9% 5.8%
Other Income/Expense, Net $1.471M $1.097M
YoY Change 34.09%
Pretax Income $39.18M $20.05M
YoY Change 95.39% -5.81%
Income Tax $9.100M $1.800M
% Of Pretax Income 23.22% 8.98%
Net Earnings $30.07M $18.27M
YoY Change 64.52% 4.67%
Net Earnings / Revenue 32.24% 28.19%
Basic Earnings Per Share $0.26 $0.16
Diluted Earnings Per Share $0.25 $0.15
COMMON SHARES
Basic Shares Outstanding 114.6M shares 114.8M shares
Diluted Shares Outstanding 122.2M shares 123.9M shares

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $307.3M $186.9M
YoY Change 64.42% 49.04%
Cash & Equivalents $84.48M $49.65M
Short-Term Investments $222.8M $137.3M
Other Short-Term Assets $5.700M $5.700M
YoY Change 0.0% 72.73%
Inventory $5.084M $5.000M
Prepaid Expenses
Receivables $26.68M $19.22M
Other Receivables $0.00 $0.00
Total Short-Term Assets $344.8M $216.9M
YoY Change 58.98% 43.81%
LONG-TERM ASSETS
Property, Plant & Equipment $880.0K $925.0K
YoY Change -4.86% 54.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $41.70M $28.80M
YoY Change 44.79% 92.0%
Other Assets $3.441M $75.00K
YoY Change 4488.0% -99.9%
Total Long-Term Assets $100.7M $103.3M
YoY Change -2.54% 12.09%
TOTAL ASSETS
Total Short-Term Assets $344.8M $216.9M
Total Long-Term Assets $100.7M $103.3M
Total Assets $445.5M $320.2M
YoY Change 39.12% 31.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.976M $9.330M
YoY Change -46.67% 18.1%
Accrued Expenses $19.59M $18.83M
YoY Change 4.04% -1.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.08M $34.22M
YoY Change -0.42% 23.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.900M $200.0K
YoY Change 850.0%
Total Long-Term Liabilities $1.900M $200.0K
YoY Change 850.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.08M $34.22M
Total Long-Term Liabilities $1.900M $200.0K
Total Liabilities $36.01M $34.46M
YoY Change 4.49% 24.39%
SHAREHOLDERS EQUITY
Retained Earnings $6.510M -$99.46M
YoY Change -106.55%
Common Stock $465.6M $427.4M
YoY Change 8.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $409.5M $285.8M
YoY Change
Total Liabilities & Shareholders Equity $445.5M $320.2M
YoY Change 39.12% 31.77%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income $30.07M $18.27M
YoY Change 64.52% 4.67%
Depreciation, Depletion And Amortization $238.0K $96.00K
YoY Change 147.92% 100.0%
Cash From Operating Activities $33.27M $23.68M
YoY Change 40.49% -31.22%
INVESTING ACTIVITIES
Capital Expenditures $42.00K $257.0K
YoY Change -83.66% 233.77%
Acquisitions
YoY Change
Other Investing Activities $19.80M -$100.0K
YoY Change -19900.0% -99.71%
Cash From Investing Activities $19.73M -$367.0K
YoY Change -5477.11% -98.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $275.0K $13.56M
YoY Change -97.97%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $205.0K -$15.29M
YoY Change -101.34% -895.47%
NET CHANGE
Cash From Operating Activities $33.27M $23.68M
Cash From Investing Activities $19.73M -$367.0K
Cash From Financing Activities $205.0K -$15.29M
Net Change In Cash $53.21M $8.025M
YoY Change 563.03% 289.75%
FREE CASH FLOW
Cash From Operating Activities $33.27M $23.68M
Capital Expenditures $42.00K $257.0K
Free Cash Flow $33.23M $23.42M
YoY Change 41.85% -31.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001088856
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-20000 USD
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-52000 USD
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
000-50679
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
CORCEPT THERAPEUTICS INC
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0487658
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
149 Commonwealth Drive
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
CY2020Q1 dei City Area Code
CityAreaCode
650
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
327-3270
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2020Q1 dei Trading Symbol
TradingSymbol
CORT
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114601708 shares
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84477000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84477000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31269000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31269000 USD
CY2020Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
222838000 USD
CY2020Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
222838000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
244693000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
244693000 USD
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26684000 USD
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26684000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19928000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19928000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
5084000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
5084000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5424000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5424000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5693000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6044000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6044000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
344776000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
344776000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
307358000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
307358000 USD
CY2020Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
11063000 USD
CY2020Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
11063000 USD
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11981000 USD
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11981000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3082000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3082000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3446000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
880000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
880000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1050000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1050000 USD
CY2020Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
41690000 USD
CY2020Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
41690000 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
39352000 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
39352000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3441000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3441000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3448000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3448000 USD
CY2020Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
40562000 USD
CY2020Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
40562000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
45677000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
45677000 USD
CY2020Q1 us-gaap Assets
Assets
445494000 USD
CY2020Q1 us-gaap Assets
Assets
445494000 USD
CY2019Q4 us-gaap Assets
Assets
412312000 USD
CY2019Q4 us-gaap Assets
Assets
412312000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4976000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4976000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7537000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7537000 USD
CY2020Q1 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
7938000 USD
CY2020Q1 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
7938000 USD
CY2019Q4 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
6477000 USD
CY2019Q4 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
6477000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19590000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19590000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23269000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23269000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1571000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1571000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1558000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
34075000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
34075000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38841000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38841000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1541000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1903000 USD
CY2020Q1 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
389000 USD
CY2019Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
386000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
36005000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
41130000 USD
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
120000 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
120000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
120000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
120000 USD
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
465528000 USD
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
465528000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
457060000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
457060000 USD
CY2020Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
62979000 USD
CY2020Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
62979000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
6510000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
6510000 USD
CY2019Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
62704000 USD
CY2019Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
62704000 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
310000 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
310000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
261000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
261000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23555000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23555000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
409489000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
409489000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
371182000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
371182000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
445494000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
445494000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
412312000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
412312000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
93247000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64829000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1878000 USD
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1240000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26123000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20244000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27535000 USD
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24389000 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
55536000 USD
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
45873000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
37711000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
18956000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1471000 USD
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1097000 USD
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
164000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
39182000 USD
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
20053000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9117000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1779000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
30065000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
18274000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
61000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
30114000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
18438000 USD
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114575000 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114844000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122226000 shares
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123895000 shares
CY2020Q1 us-gaap Profit Loss
ProfitLoss
30065000 USD
CY2019Q1 us-gaap Profit Loss
ProfitLoss
18274000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7918000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6696000 USD
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5095000 USD
CY2019Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
926000 USD
CY2020Q1 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
177000 USD
CY2019Q1 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
634000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
238000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
96000 USD
CY2020Q1 cort Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
364000 USD
CY2019Q1 cort Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
413000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6756000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1630000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1328000 USD
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-910000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-351000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1999000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-7000 USD
CY2019Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
25000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2600000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
953000 USD
CY2020Q1 cort Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
1461000 USD
CY2019Q1 cort Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
1016000 USD
CY2020Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3676000 USD
CY2019Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-4956000 USD
CY2020Q1 cort Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-349000 USD
CY2019Q1 cort Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-357000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
33269000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
23681000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
257000 USD
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
68245000 USD
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
70825000 USD
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
48469000 USD
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
70935000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19734000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-367000 USD
CY2020Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
480000 USD
CY2019Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2435000 USD
CY2020Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
275000 USD
CY2019Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
13555000 USD
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
CY2019Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4169000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
205000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-15289000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
53208000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8025000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31269000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41625000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84477000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49650000 USD
CY2020Q1 cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
0 USD
CY2019Q1 cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
931000 USD
CY2020Q1 cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
0 USD
CY2019Q1 cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
1878000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
275882000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3366000 USD
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5100000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6724000 USD
CY2019Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
164000 USD
CY2019Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
13555000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
18274000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
285755000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
371182000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
480000 USD
CY2020Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
275000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7988000 USD
CY2020Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
49000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
30065000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
409489000 USD
CY2020Q1 cort Number Of Series Of Selective Cortisol Modulators
NumberOfSeriesOfSelectiveCortisolModulators
4 series
CY2020Q1 cort Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
0 USD
CY2019Q4 cort Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
1389000 USD
CY2020Q1 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
10024000 USD
CY2019Q4 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
10086000 USD
CY2020Q1 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
6123000 USD
CY2019Q4 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
5930000 USD
CY2020Q1 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
16147000 USD
CY2019Q4 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
17405000 USD
CY2020Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
11063000 USD
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11981000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
5084000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5424000 USD
CY2020Q1 cort Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
2446000 USD
CY2019Q4 cort Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
2378000 USD
CY2020Q1 cort Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1566000 USD
CY2019Q4 cort Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1328000 USD
CY2020Q1 cort Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
880000 USD
CY2019Q4 cort Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1050000 USD
CY2020Q1 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
9275000 USD
CY2019Q4 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
8209000 USD
CY2020Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4210000 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
472000 USD
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3837000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12331000 USD
CY2020Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
707000 USD
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
491000 USD
CY2020Q1 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
697000 USD
CY2019Q4 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
1087000 USD
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
421000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
367000 USD
CY2020Q1 cort Accrued Manufacturing Costs
AccruedManufacturingCosts
180000 USD
CY2019Q4 cort Accrued Manufacturing Costs
AccruedManufacturingCosts
33000 USD
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
263000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
279000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19590000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23269000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
331755000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
302506000 USD
CY2020Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
1400000 USD
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1000000.0 USD
CY2020Q1 cort Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
P2Y
CY2020Q1 cort Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
P5M
CY2019Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 USD
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
391000 USD
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
379000 USD
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P24M
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12M
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.050
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.050
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1598000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2130000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
535000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4263000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1151000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3112000 USD
CY2020Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 USD
CY2020Q1 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0 USD
CY2020Q1 cort Number Of Stock Option Plans
NumberOfStockOptionPlans
2 stock_option_plan
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100000 shares
CY2019Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1500000 shares
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
70000 USD
CY2019Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
28000 USD
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
7988000 USD
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
6724000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
30065000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
18274000 USD
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114575000 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114844000 shares
CY2020Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7651000 shares
CY2019Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9051000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122226000 shares
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123895000 shares
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
27000000.0 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24400000 shares
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9100000 USD
CY2020Q1 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
100000 USD
CY2020Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-5100000 USD
CY2020Q1 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
4000000.0 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1800000 USD
CY2019Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-900000 USD
CY2019Q1 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
900000 USD

Files In Submission

Name View Source Status
0001628280-20-006270-index-headers.html Edgar Link pending
0001628280-20-006270-index.html Edgar Link pending
0001628280-20-006270.txt Edgar Link pending
0001628280-20-006270-xbrl.zip Edgar Link pending
cort-20200331.htm Edgar Link pending
cort-20200331.xsd Edgar Link pending
cort-20200331_cal.xml Edgar Link unprocessable
cort-20200331_def.xml Edgar Link unprocessable
cort-20200331_htm.xml Edgar Link completed
cort-20200331_lab.xml Edgar Link unprocessable
cort-20200331_pre.xml Edgar Link unprocessable
cort33120ex311.htm Edgar Link pending
cort33120ex312.htm Edgar Link pending
cort33120ex321.htm Edgar Link pending
cort33120ex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending